NOVABAY PHARMACEUTICALS, Inc. (AM:NBY)

1.96

+0.01 (0.51%)

NOVABAY PHARMACEUTICALS, Inc. (AM:NBY) Delayed :
Previous Close	$1.95	52 Week High	$3.24
Open	$1.99	52 Week Low	$1.00
Day High	$1.99	P/E	N/A
Day Low	$1.96	EPS	$-0.09
Volume	8,800
More NBY Info: Chart SEC Filings Profile Historical Options

What is this?Friends, Peers and Foes

Ticker	# Stories	Ticker	# Stories
ACL	3	CADE	2

View All Entities

Nov 13, 2009 09:07 AM NovaBay Pharma (NBY) Posts Q3 Break-Even EPS, 1c Better Than Estimates

Nov 13, 2009 09:07 AM NovaBay Pharma (NBY) Posts Q3 Break-Even EPS, 1c Better Than Estimates
Oct 19, 2009 07:11 AM NovaBay Pharmaceuticals (NBY) Names Dr. Mark Andersone as Chief Scientific Officer
Aug 24, 2009 09:32 AM NovaBay Pharma (NBY) to Present New Pre-Clinical Data on NVC-422 for Use in Onychomycosis
Aug 21, 2009 10:29 AM NovaBay Pharmaceuticals (NBY) Prices 1.225 Million Share Offering
Jul 6, 2009 08:42 AM Alcon (ACL) Begins Phase 2 Trial of NovaBay's (NBY) NVC-422

Nov 13, 2009 09:00AM NovaBay Pharmaceuticals Reports Third Quarter Financials and Provides Update on Pipeline of Anti-Infective Compounds
Oct 30, 2009 09:30AM NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
Oct 28, 2009 07:30AM NovaBay to Hold Conference Call to Review Aganocide Data Presented at the Infectious Diseases Society of America Meeting
Oct 22, 2009 07:00AM NovaBay Pharmaceuticals to Present at 8th Annual Bio Investor Forum 2009 in San Francisco
Oct 19, 2009 07:00AM NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer

Nov 5, 2009 04:56PM Form 10-Q CADENCE FINANCIAL CORP For: Sep 30
Oct 26, 2009 04:54PM Form 8-K CADENCE FINANCIAL CORP For: Oct 26
Oct 21, 2009 07:31PM Form 4 NovaBay Pharmaceuticals, For: Oct 21 Filed by: Anderson Mark Brian
Oct 8, 2009 01:10PM Form 4 Najafi Ramin For: Oct 06
Oct 7, 2009 03:06PM Form 4 Khosrovi Behzad For: Oct 06

No comments are currently available.